Advances in the field of cannabinoid–opioid cross‐talk
Tóm tắt
A remarkable amount of literature has been generated demonstrating the functional similarities between the endogenous opioid and cannabinoid systems. Anatomical, biochemical and molecular data support the existence of reciprocal interactions between these two systems related to several pharmacological responses including reward, cognitive effects, and the development of tolerance and dependence. However, the assessment of the bidirectionality of these effects has been difficult due to their variety and complexity. Reciprocal interactions have been well established for the development of physical dependence. Cross‐tolerance and cross‐sensitization, although not always bidirectional, are also supported by a number of evidence, while less data have been gathered regarding the relationship of these systems in cognition and emotion. Nevertheless, the most recent advances in cannabinoid–opioid cross‐modulation have been made in the area of drug craving and relapse processes. The present review is focused on the latest developments in the cannabinoid–opioid cross‐modulation of their behavioural effects and the possible neurobiological substrates involved.
Từ khóa
Tài liệu tham khảo
Braida D, 2001, Intracerebral self‐administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system, Eur J Pharmacol, 413, 227, 10.1016/S0014-2999(01)00766-X
Devane WA, 1988, Determination and characterization of a cannabinoid receptor in rat brain, Mol Pharmacol, 34, 605
Fan F, 1994, Development of cross‐tolerance between delta 9‐tetrahydrocannabinol, CP 55,940 and WIN 55,212, J Pharmacol Exp Ther, 271, 1383
Felder CC, 1992, Cannabinoid agonists stimulate both receptor‐ and non‐receptor‐mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones, Mol Pharmacol, 42, 838
Fride E, 2003, Molecular Biology of Drug Addiction, 173
Howlett AC, 1984, Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes, Mol Pharmacol, 26, 532
Kieffer BL, 2003, Molecular Biology of Drug Addiction, 3
Lichtman AH, 2001, Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)‐tetrahydrocannabinol and morphine‐dependent mice, J Pharmacol Exp Ther, 298, 1007
Maldonado R, 1992, Role of different brain structures in the expression of the physical morphine withdrawal syndrome, J Pharmacol Exp Ther, 261, 669
Menard DP, 1996, A calcitonin gene‐related peptide receptor antagonist prevents the development of tolerance to spinal morphine analgesia, J Neurosci, 16, 2342, 10.1523/JNEUROSCI.16-07-02342.1996
Navarro M, 2001, Functional interaction between opioid and cannabinoid receptors in drug self‐administration, J Neurosci, 21, 5344, 10.1523/JNEUROSCI.21-14-05344.2001
Onaivi ES, 1990, Pharmacological characterization of cannabinoids in the elevated plus maze, J Pharmacol Exp Ther, 253, 1002
Rodríguez de Fonseca F, 1996, Corticotropin‐releasing factor (CRF) antagonist [D‐Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU‐210 on defensive‐withdrawal behavior in rats, J Pharmacol Exp Ther, 276, 56
Smith PB, 1994, Interactions between delta 9‐tetrahydrocannabinol and kappa opioids in mice, J Pharmacol Exp Ther, 268, 1381
Valverde O, 2000, Cannabinoid withdrawal syndrome is reduced in pre‐proenkephalin knock‐out mice, J Neurosci, 20, 9284, 10.1523/JNEUROSCI.20-24-09284.2000
Valverde O, 2004, Involvement of the endogenous opioid system in cannabinoid responses, Curr Med Chem, 4, 183
Vigano D, 2005, Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems, Psychopharmacology (Berl), 182, 527, 10.1007/s00213-005-0114-4